Anti-asthma drugs containing salmetrol could face tougher challenges in Indian market as US FDA has issued strong concern about the use of long-acting beta agonists (LABAs) to treat the disease.

India's Lupin continued to defend its position on Nexium generic even as AstraZeneca strengthened its case by roping in more patents to the lawsuit alleging infringement of esomeprazole magnesium product's IP rights.

Indian generic companies stand to gain considerably as the global generic drug industry continues to witnessed sales and volume growth of prescription generic drugs for almost a decade to 2009.

The German drug major Bayer AG is planning to move India's Supreme Court seeking protection for its Nexavar (sorafenib) even as Cipla prepares for the launch of a generic version of the kidney cancer drug in a couple of months time following the Delhi High Court's latest verdict upholding an earlier judgment in the case.

Cough medication Corex by Pfizer has emerged the top selling brand in India with annual sales of Rs 182 crore during the year 2009, according to Stockist Secondary Audit data from drug sales tracking agency, ORG-IMS India.

Ballabgarh in north Indian state of Haryana could come up in the world map for an altogether new reason: The village has perhaps the lowest number of Alzheimer's disease risk in the world, according to a report.

US FDA has asked Daiichi-controlled Ranbaxy to undertake concrete steps to ensure that all of the company's facilities involved in manufacturing products to US market confirm with the regulator's cGMP requirements.

Prices of drugs to treat cancer and AIDS could become cheaper in India as the government is proposing a total customs duty waiver for these life-saving drugs in the budget fiscal year 2010-11, reports said.

The government of India has brought into effect stricter norms for obtaining No Objection Certificates (NOCs) for pharmaceutical exporters.

The controversial anti-obesity drug sibutramine could be banned in India, reports said.